{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:44:37Z","timestamp":1787168677856,"version":"build-2736575974"},"reference-count":71,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Antibody\u2013drug conjugates (ADCs) have rapidly changed the breast cancer treatment landscape. The unique technology allows for targeted delivery of a cytotoxic payload to cancer cells expressing a specific antigen, thereby delivering high cytotoxic loads while decreasing off\u2010target effects. Efforts to improve ADC technology through optimization of the antibody, cytotoxic payload, and chemical linkers are ongoing. Novel target antigens are also being explored. Clinically, given the success of ADCs in the treatment of metastatic disease, efforts are ongoing to move these therapies into the early\u2010stage setting with the aim of improving outcomes and increasing the likelihood of cure.<\/jats:p>","DOI":"10.1002\/cncr.70420","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T03:14:22Z","timestamp":1780370062000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antibody\u2013drug conjugates in breast cancer"],"prefix":"10.1002","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3295-0612","authenticated-orcid":false,"given":"Elizabeth A.","family":"Sakach","sequence":"first","affiliation":[{"name":"Winship Cancer Institute Emory University  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2642-865X","authenticated-orcid":false,"given":"Jane L.","family":"Meisel","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute Emory University  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather L.","family":"McArthur","sequence":"additional","affiliation":[{"name":"UT Southwestern Medical Center  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(17)30312\u20101"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1209124"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.12.001"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(23)00725\u20100"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(22)02420\u20105"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.17_suppl.lba1008"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.17_suppl.lba1001"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.18632\/genesandcancer.40"},{"key":"e_1_2_11_10_1","doi-asserted-by":"crossref","unstructured":"Jhaveri1 YP KL Barrios3C Curigliano4G et\u00a0al.Sacituzumab govitecan vs chemotherapy as first therapy after endocrine therapy in HR+\/HER2\u2212 (IHC 0 1+ 2+\/ISH\u2212) metastatic breast cancer: primary results from ASCENT\u201007. Paper presented at: SABCS;2025 San Antonio TX.","DOI":"10.1158\/1557-3265.SABCS25-GS1-09"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511734"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1859"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2511734"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2202809"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2508959"},{"key":"e_1_2_11_16_1","doi-asserted-by":"crossref","unstructured":"DentR ShaoZ SchmidP et\u00a0al.First\u2010line datopotamab deruxtecan (Dato\u2010DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple\u2010negative breast cancer (TNBC) for whom immunotherapy was not an option: primary results from the randomised phase 3 TROPION\u2010Breast02 trial. Paper presented at: ESMO;2025.","DOI":"10.1016\/j.annonc.2025.09.031"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251327992"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1557\u20103265.sabcs25\u2010ps1\u201009\u201002"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.ccr\u201015\u20102822"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12966"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.can\u201008\u20101776"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.02.020"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(19)30097\u2010x"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1914510"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2115022"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.04.516"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511218"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201002600"},{"key":"e_1_2_11_29_1","volume-title":"San Antonio Breast Cancer Symposium","author":"Cort\u00e9s JJG\u2010M","year":"2024"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(19)30863\u20100"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.54.5384"},{"key":"e_1_2_11_32_1","article-title":"Circulating tumor DNA (ctDNA) dynamics as a predictor of treatment response in metastatic breast cancer (mBC)","author":"Pedram Razavi LC","year":"2025","journal-title":"ASCO"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.1009"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1814017"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2203690"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2407086"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.10.019"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2406070"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.sabcs21\u2010ot1\u201002\u201003"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2514661"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.10.019"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.1003"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae088"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.sabcs23\u2010po1\u201005\u201009"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.00920"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2028485"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010023\u201002478\u20102"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523\u2010025\u201000736\u20109"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.018"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.511"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.15_suppl.tps602"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.tps619"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241248336"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523\u2010025\u201000748\u20105"},{"key":"e_1_2_11_56_1","doi-asserted-by":"crossref","unstructured":"MaiN KlarM FerraroE BrombergM.Real world ourcomes of sequential ADC therapy in metastatic breast cancer: patients treated with sacituzumab govitecan and trastuzumab deruxtecan. Paper presented at: ASCO 2024.2024.","DOI":"10.1200\/JCO.2024.42.16_suppl.1085"},{"key":"e_1_2_11_57_1","unstructured":"Rachel Occhiogrosso AbelmanLS FellGG RyanP et\u00a0al.Sequential use of antibody\u2010drug conjugate after antibody\u2010drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study. Paper presented at: ASCO. 2023 2023."},{"key":"e_1_2_11_58_1","unstructured":"TarantinoP LeeD FoldiJ SoulosP.Real\u2010world efficacy of immediate subsequent lines of therapy after trastuzumab deruxtecan (T\u2010DXd) in patients with metastatic breast cancer (MBC) \u2013 retrospective study from the nationwide Flatiron database. Paper presented at: SABCS;2024; San Antonio TX."},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12577"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.332"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00882"},{"issue":"16","key":"e_1_2_11_62_1","article-title":"HERTHENA\u2010Breast03: a phase 2, randomized, open\u2010label study evaluating neoadjuvant patritumab deruxtecan + pembrolizumab before or after pembrolizumab + chemotherapy for early\u2010stage TNBC or HR\u2010low+\/HER2\u2212 breast cancer","volume":"43","author":"O'Shaughnessy J","year":"2025","journal-title":"J Clin Oncol"},{"key":"e_1_2_11_63_1","doi-asserted-by":"crossref","unstructured":"HamiltonE H.H. AbuhadraN et\u00a0al.Clinical activity of emiltatug ledadotin (Emi\u2010Le) a B7\u2010H4\u2010directed ADC in patients with TNBC who received at least one prior topoisomerase\u20101 inhibitor (Topo\u20101) ADC. Paper presented at: ESMO Breast Congress;2025; Munich Germany.","DOI":"10.1016\/j.esmoop.2025.104870"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010025\u201003630\u2010w"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2310890"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.1020"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.tps1123"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbad027"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113738"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010025\u201001704\u20103"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010023\u201001509\u20102"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571\u2010023\u201000850\u20102"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70420","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70420","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:51:15Z","timestamp":1780411875000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":71,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2026,6,1]]}},"alternative-id":["10.1002\/cncr.70420"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70420","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"2025-09-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70420"}}